Table 2 Estimated comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines for SARS-CoV-2 infection
From: Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Population | Number | No. of Events | Mean follow up, months | Incidence ratea, per 1000 person-months | Rate differencea (95%CI), per 1000 person-months | Hazard ratioa (95%CI) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
BNT162b2 | ChAdOx1 | BNT162b2 | ChAdOx1 | BNT162b2 | ChAdOx1 | BNT162b2 | ChAdOx1 | |||
Overall | 536,371 | 774,704 | 20,070 | 31,611 | 6.65 | 7.33 | 3.65 | 5.25 | -1.60 (-1.76, -1.43) | 0.69 (0.68, 0.71) |
Sex | ||||||||||
 Male | 252,646 | 384,903 | 8,582 | 14,666 | 6.34 | 7.25 | 3.42 | 4.85 | -1.44 (-1.67, -1.20) | 0.70 (0.68, 0.73) |
 Female | 283,725 | 389,801 | 11,488 | 16,945 | 6.93 | 7.40 | 3.85 | 5.59 | -1.74 (-1.98, -1.50) | 0.68 (0.66, 0.71) |
Age | ||||||||||
 Age>=65 | 132,624 | 235,594 | 2,482 | 4,886 | 8.49 | 8.36 | 2.17 | 2.72 | -0.55 (-0.74, -0.36) | 0.79 (0.75, 0.84) |
 Age<65 | 403,747 | 539,110 | 17,588 | 26,725 | 6.07 | 6.89 | 5.15 | 7.62 | -2.47 (-2.76, -2.19) | 0.67 (0.65, 0.70) |
Study period | ||||||||||
 Alpha-variant predominance | 356,679 | 739,203 | 1,252 | 1,227 | 2.61 | 2.24 | 0.84 | 0.94 | -0.10 (-0.23, 0.04) | 0.89 (0.80, 1.00) |
 Delta-variant predominance | 179,692 | 35,501 | 8,413 | 1,996 | 4.31 | 4.86 | 8.02 | 11.99 | -3.96 (-5.02, -2.90) | 0.67 (0.62, 0.72) |
Including prior infected population | 561,140 | 803,200 | 20,398 | 32,007 | 6.63 | 7.32 | 3.65 | 5.28 | -1.62 (-1.79, -1.47) | 0.69 (0.67, 0.71) |
Received two doses | 491,591 | 730,363 | 12,229 | 28,196 | 6.96 | 7.58 | 3.01 | 4.59 | -1.58 (-1.73, -1.42) | 0.65 (0.64, 0.67) |
Received one dose | 29,701 | 21,870 | 2,138 | 905 | 4.26 | 5.13 | 9.07 | 8.91 | 0.16 (-1.31, 1.64) | 1.01 (0.91, 1.14) |